Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.

Fernando Manuel Vargas Madueno; Wenrui Duan; Zuanel Diaz; John Paul Diaz; Federico Albrecht; Siddharta Venkatappa; Eric Douglas Schroeder; Santiago Aparo; Vanessa Yanek; Gail Walker; Miguel Villalona

doi:10.1200/jco.2018.36.15_suppl.tps3108

Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.

Fernando Manuel Vargas Madueno
, Wenrui Duan
, Zuanel Diaz
, John Paul Diaz
, Federico Albrecht
, Siddharta Venkatappa
, Eric Douglas Schroeder
, Santiago Aparo
, Vanessa Yanek
, Gail Walker
, Miguel Villalona

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	36
DOIs	https://doi.org/10.1200/jco.2018.36.15_suppl.tps3108
State	Published - May 20 2018

Disciplines

Oncology
Pathology
Medicine and Health Sciences

Access to Document

10.1200/jco.2018.36.15_suppl.tps3108License: Unspecified

Cite this

@article{55ead21d6a274fcba91ae0cd0cea4bcc,

title = "Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.",

author = "Madueno, \{Fernando Manuel Vargas\} and Wenrui Duan and Zuanel Diaz and Diaz, \{John Paul\} and Federico Albrecht and Siddharta Venkatappa and Schroeder, \{Eric Douglas\} and Santiago Aparo and Vanessa Yanek and Gail Walker and Miguel Villalona",

note = "TPS3108 Background: Recent studies have shown that patients with mismatch repair deficiency have an increased response rate to immune checkpoint inhibitors (ICI). This led to the tissue-agnostic FDA approval of pembrolizumab (PEM).",

year = "2018",

month = may,

day = "20",

doi = "10.1200/jco.2018.36.15\_suppl.tps3108",

language = "American English",

volume = "36",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.

AU - Madueno, Fernando Manuel Vargas

AU - Duan, Wenrui

AU - Diaz, Zuanel

AU - Diaz, John Paul

AU - Albrecht, Federico

AU - Venkatappa, Siddharta

AU - Schroeder, Eric Douglas

AU - Aparo, Santiago

AU - Yanek, Vanessa

AU - Walker, Gail

AU - Villalona, Miguel

N1 - TPS3108 Background: Recent studies have shown that patients with mismatch repair deficiency have an increased response rate to immune checkpoint inhibitors (ICI). This led to the tissue-agnostic FDA approval of pembrolizumab (PEM).

PY - 2018/5/20

Y1 - 2018/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.TPS3108

U2 - 10.1200/jco.2018.36.15_suppl.tps3108

DO - 10.1200/jco.2018.36.15_suppl.tps3108

M3 - Article

VL - 36

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency.

Disciplines

Access to Document

Other files and links

Cite this